Moderate-to-Severe Diarrhea and Stunting Among Children Younger Than 5 Years: Findings From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.

Stunting affects >20% of children <5 years old worldwide and disproportionately impacts underserved communities. The Vaccine Impact on Diarrhea in Africa (VIDA) Study examined the association between an episode of moderate-to-severe diarrhea (MSD) and the risk of subsequent stunting in children <5 years living in 3 sub-Saharan African countries. In this prospective, matched, case-control study among children <5 years, data were collected over 36 months from 2 groups. "Children with MSD" visited a health center within 7 days of illness onset experiencing ≥3 loose stools/day plus sunken eyes, poor skin turgor, dysentery, intravenous rehydration, or hospitalization. "Children without MSD" were enrolled from the community within 14 days of the index MSD child; they were diarrhea-free during the previous 7 days and were matched to the index case by age, sex, and residence. Using generalized linear mixed-effects models, we estimated the effect of an MSD episode on odds of being stunted, defined as height-for-age z-scores <-2, at a follow-up visit 2-3 months post-enrollment. The proportion of stunting at enrollment was similar when 4603 children with MSD and 5976 children without MSD were compared (21.8% vs 21.3%; P = .504). Among children not stunted at enrollment, those with MSD had 30% higher odds of being stunted at follow-up than children without MSD after controlling for age, sex, study site, and socioeconomic status (adjusted OR: 1.30; 95% CI: 1.05-1.62: P = .018). Children <5 years in sub-Saharan Africa without stunting experienced an increased likelihood of stunting during 2-3 months following an episode of MSD. Strategies for control of early childhood diarrhea should be integrated into programs intended to reduce childhood stunting.

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Potential conflicts of interest. I. G. C. reports receiving grant funding from the National Heart, Lung, and Blood Institute (NHLBI) and consulting fees from the University of California, San Francisco. They also report receiving travel support from Research in Implementation Science for Equity program from the University of San Francisco institute to travel to San Francisco. K. L. K. reports consultation fees and travel support from PATH and the University of Washington related to diarrheal diseases and grant support to her institution from the National Institute of Allergy and Infections Diseases, Institut Pasteur, and the Bill & Melinda Gates Foundation. M.-A. W. reports receiving funding from the Centers for Disease Control and Prevention (CDC) and Institute of Tropical Medicine. S. M. T. reports multiple grants paid to her institution from the National Institutes of Health (NIH), Bill & Melinda Gates Foundation (BMGF), Wellcome Trust, Affinivax, Lumen Biosciences, PATH, and Medical Research Council. She also reports payments as royalties related to intellectual property for Salmonella vaccines and Klebsiella/Pseudomonas vaccines and consulting fees and travel support from the University of Washington for a grant proposal. She also reports holding multiple planned, issued, and pending patents on Salmonella, Klebsiella, and Pseudomonas vaccines and hold multiple unpaid committee roles with the American Society of Tropical Medicine and Hygiene. Y. L. reports receiving the following grants or contracts paid to their institution: R01NS122855, U54CK000615-01, 1R18 HS027750-01, R03 AG067927, U01 AI143493, U01 AI148054, U01 AI148081, NCT04078022, HHS-NIH-NIAID-BAA2018, R01 HD093946-01, 2R01-DA026868-06A1, 2R01-AA014988-12A1, R01 AA014988-S1, R01 DK109323, R01-NR016269, Geneva Foundation (National Institute for Allergy and Infectious Diseases [NIAID] prime), R01-HD075936, and BAA FY2018-OADS-01. They also report serving as the Data Safety Monitoring Board statistician for the clinical trial entitled “Matching Perfusion and Metabolic Activity in HFpEF (MPMA),” and reviewed data from National Institute on Drug Abuse/National Institute on Alcohol Abuse and Alcoholism (NIDA/NIAAA) studies involving human subjects. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.